Scroll

dobutamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics	937	34368-04-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dobutamine dobutamine hydrochloride dobutamine HCl	A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY. Molecular weight: 301.39 Formula: C18H23NO3 CLOGP: 2.43 LIPINSKI: 0 HAC: 4 HDO: 4 TPSA: 72.72 ALOGS: -4.34 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dobutamine
dobutamine hydrochloride
dobutamine HCl

A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.

Molecular weight: 301.39
Formula: C18H23NO3
CLOGP: 2.43
LIPINSKI: 0
HAC: 4
HDO: 4
TPSA: 72.72
ALOGS: -4.34
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.50	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
CL (Clearance)	115 mL/min/kg	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.13 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 4 of 4 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
July 18, 1978	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Stress cardiomyopathy	175.58	27.54	50	3705	9400	63475867
Cardiogenic shock	140.19	27.54	49	3706	17883	63467384
Drug ineffective	96.91	27.54	198	3557	1044567	62440700
Multiple organ dysfunction syndrome	83.32	27.54	48	3707	56704	63428563
Cardiac failure	63.54	27.54	48	3707	89094	63396173
Toxic epidermal necrolysis	55.57	27.54	28	3727	25306	63459961
Vasoplegia syndrome	55.24	27.54	14	3741	1685	63483582
Local anaesthetic systemic toxicity	53.10	27.54	12	3743	887	63484380
Septic shock	45.51	27.54	35	3720	66594	63418673
Drug ineffective for unapproved indication	45.17	27.54	27	3728	34036	63451231

Showing 1 to 10 of 22 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	523.48	31.00	150	6844	8451	34941486
Appendicitis	451.12	31.00	152	6842	14655	34935282
Multiple organ dysfunction syndrome	403.52	31.00	227	6767	76339	34873598
Stress	394.44	31.00	167	6827	30180	34919757
Ventricular fibrillation	313.69	31.00	131	6863	22823	34927114
Ascites	303.02	31.00	159	6835	46412	34903525
Abdominal distension	258.64	31.00	155	6839	58337	34891600
Blood phosphorus increased	225.94	31.00	77	6917	7644	34942293
Hyponatraemia	207.47	31.00	154	6840	82537	34867400
General physical health deterioration	178.59	31.00	170	6824	128099	34821838

Showing 1 to 10 of 36 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	583.80	25.15	149	10162	8402	79725675
Multiple organ dysfunction syndrome	468.23	25.15	252	10059	119994	79614083
Appendicitis	461.02	25.15	151	10160	20643	79713434
Ventricular fibrillation	372.57	25.15	144	10167	31782	79702295
Ascites	318.03	25.15	167	10144	75395	79658682
Stress	315.44	25.15	169	10142	79443	79654634
Blood phosphorus increased	248.91	25.15	80	10231	10267	79723810
Abdominal distension	237.36	25.15	163	10148	119487	79614590
Sepsis	209.05	25.15	213	10098	269215	79464862
Stress cardiomyopathy	207.25	25.15	71	10240	11095	79722982

Showing 1 to 10 of 58 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	C01CA07	CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents
CHEBI has role	CHEBI:35522	beta-adrenergic agonists
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:38147	cardiotonic drugs
FDA EPC	N0000175555	beta-Adrenergic Agonist
FDA MoA	N0000000245	Adrenergic beta-Agonists
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D058665	Adrenergic beta-1 Receptor Agonists
MeSH PA	D000318	Adrenergic beta-Agonists

Showing 1 to 10 of 16 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Cardiogenic shock	indication	89138009
Decompensated cardiac failure	indication	195111005
Stress echocardiography using dobutamine	indication	703338002
Cardiac Decompensation	indication
Cardiac Decompensation Post Cardiac Surgery	indication
Organic Cardiac Disease	indication
Ventricular premature beats	contraindication	17338001
Myocardial infarction	contraindication	22298006	DOID:5844
Hypovolemia	contraindication	28560003
Hypertensive disorder	contraindication	38341003	DOID:10763

Showing 1 to 10 of 14 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.98	acidic
pKa2	10.59	acidic
pKa3	13.49	acidic
pKa4	9.03	Basic

Showing 1 to 4 of 4 entries

Previous1Next

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	AGONIST	EC50	5.50	WOMBAT-PK	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	EC50	6.20	WOMBAT-PK	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	5.98	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.00	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.42	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.87	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	5.77	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	6.91	DRUG MATRIX
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		Ki	6.32	CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.35	DRUG MATRIX

Showing 1 to 10 of 31 entries

Previous1 2 3 4Next

External reference:

Show entries

Search:

ID	Source
Y00	PDB_CHEM_ID
000614	NDDF
000615	NDDF
203121	RXNORM
26523005	SNOMEDCT_US
2871	MMSL
3340	INN_ID
36811	PUBCHEM_CID
387145002	SNOMEDCT_US
3S12J47372	UNII

Showing 1 to 10 of 26 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9141	INJECTION, SOLUTION	12.50 mg	INTRAVENOUS	ANDA	20 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2344	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2344	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	14335-171	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	14335-172	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	21 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1330	INJECTION, SOLUTION	200 mg	INTRAVENOUS	NDA	12 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1330	INJECTION, SOLUTION	200 mg	INTRAVENOUS	NDA	12 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1337	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	12 sections
DOBUTAMINE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1337	INJECTION, SOLUTION, CONCENTRATE	12.50 mg	INTRAVENOUS	ANDA	12 sections
Dobutamine	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5717	INJECTION, SOLUTION	12.50 mg	INTRAVENOUS	ANDA	11 sections

Showing 1 to 10 of 24 entries

Previous1 2 3Next